Market Newsdesk

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

Top-Line Results Expected in the First Half of 2023

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced completion of enrollment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of allergic conjunctivitis.

“Today, millions of allergic conjunctivitis patients rely on therapies that may not provide sufficient relief or cannot be used chronically due to serious side effects,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “Reproxalap, which has demonstrated rapid and durable improvement in the symptoms and signs of allergic conjunctivitis across a number of clinical trials, could signify the first new therapeutic mechanism of action in decades for patients suffering from this persistently disturbing condition.”

The randomized, double-masked, crossover, vehicle-controlled Phase 3 clinical trial enrolled 131 seasonal allergic conjunctivitis patients who were evaluated for 3.5 hours in an allergen chamber designed to simulate real-world pollen exposure. Consistent with pivotal trials of approved allergic conjunctivitis products, the primary endpoint of INVIGORATE-2 is patient-reported ocular itching. Top-line results from the trial are expected in the first half of 2023.

The protocol of INVIGORATE-2 is substantially identical to that of the Phase 3 INVIGORATE clinical trial and a Phase 2 clinical trial,¹ both of which achieved the ocular itching endpoint (P<0.001).

About Reproxalap

Reproxalap, an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications. Reproxalap has been studied in more than 2,300 patients with no observed clinically significant safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.

About Allergic Conjunctivitis

Allergic conjunctivitis is the most common inflammatory disease that affects the front of the eye, and is characterized by itching, redness, and tearing.² The signs and symptoms of allergic conjunctivitis are persistently disturbing, affecting quality of life and leading to loss of work that can create a substantial economic burden for patients and their families.³ Although allergic conjunctivitis is commonly treated with antihistamines, up to 60% of patients require adjunctive therapy and up to 40% of patients require corticosteroids,⁴ which can lead to significant ocular toxicity.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease (under U.S. Food and Drug Administration New Drug Application Review) and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma (under U.S. Food and Drug Administration New Drug Application Priority Review), proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing of top-line results of the Phase 3 INVIGORATE-2 clinical trial of reproxalap for the treatment of allergic conjunctivitis. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “contemplates,” “likely,” “potential,” “continue,” “ongoing,” “aim,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra’s product candidates, including as a result of the FDA not accepting Aldeyra’s regulatory filings, requiring additional clinical trials or data prior to review or approval of such filings; the ability to maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra’s product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; the current and potential future impact of the COVID-19 pandemic on Aldeyra’s business, results of operations, and financial position; uncertainty as to Aldeyra’s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra’s product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra’s cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra’s product candidates; Aldeyra’s expectations regarding competition; Aldeyra’s anticipated growth strategies; Aldeyra’s ability to attract or retain key personnel; Aldeyra’s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra’s ability to establish and maintain development partnerships; Aldeyra’s ability to successfully integrate acquisitions into its business; Aldeyra’s expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, including the COVID-19 pandemic and subsequent public health measures, and war or other military actions, that may affect Aldeyra’s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra’s ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra’s business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at https://www.sec.gov/. Additional factors may be described in those sections of Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, expected to be filed with the SEC in the second quarter of 2023.

In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

¹ Clark D, Karpecki P, Salapatek AM, Sheppard JD, Brady TC. Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure. Clin Ophthalmol. 2022 Jan 4;16:15-23.

² The American Academy of Allergy, Asthma & Immunology (AAAAI), Allergic Conjunctivitis Defined.

³ Andrew D. Pitt, Andrew F. Smith, Lynda Lindsell, Li Wern Voon, Peter W. Rose & Anthony J. Bron (2004) Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire, Ophthalmic Epidemiology, 11:1, 17-33.

⁴ Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118–1125.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005782/en/

Investor & Media

Scott Solomon

Sharon Merrill Associates, Inc.

Senior Vice President

(857) 383-2409

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Pharmaceutical Health Clinical Trials

MEDIA:

Logo

Stratasys Board of Directors Unanimously Rejects the Nano Dimension Revised Unsolicited Proposal of $20.05 Per Share

Proposal Substantially Undervalues Stratasys in Light of the Company’s Prospects and Is Not in the Best Interests of Stratasys and its Shareholders

Nano Dimension’s Authority to Make and Follow Through on an Acquisition Proposal Remains in Question

MINNEAPOLIS & REHOVOT, Israel–(BUSINESS WIRE)–
Stratasys Ltd. (Nasdaq: SSYS) (the “Company”), a leader in polymer 3D printing solutions, today announced that its Board of Directors has unanimously rejected the revised unsolicited proposal received from Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano”) on April 3, 2023 to acquire Stratasys for $20.05 per share in cash.

Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, the Stratasys Board of Directors carefully reviewed and evaluated the revised proposal. Following its review, the Stratasys Board concluded that Nano’s proposal continues to substantially undervalue Stratasys in light of its standalone prospects and is not in the best interests of Stratasys and its shareholders.

Additionally, the general composition and legitimacy of Nano’s board and management, and authority to submit and follow through on a bona fide acquisition proposal, remain unclear due to Nano’s pending court litigation with its largest shareholder, Murchinson Ltd. Murchinson requisitioned a meeting of Nano shareholders to, among other things, remove Nano CEO Mr. Yoav Stern and three other Nano directors and elect two new directors, with the goal of “reporting out to shareholders within 60 days of new directors being seated a cohesive strategy for enhancing value.” Murchinson announced that the Nano shareholder meeting was held on March 20, 2023, and that all of the changes regarding the composition of Nano’s board, including the removal of Mr. Stern, were approved by 92% of the Nano shares voting. Murchinson, Nano and Mr. Stern are now involved in litigation as to who in fact is currently leading Nano. Thus, Nano’s revised proposal, in addition to substantially undervaluing Stratasys, is subject to significant uncertainty as to the composition, leadership and decision-making authority of Nano’s board.

In this regard, the Stratasys Board and management team are concerned that a take-over proposal while Nano’s authority is unclear legally and subject to a court ruling would expose Stratasys, its shareholders and other stakeholders to the harmful spillover effects of what, in Stratasys’ judgment, is an unprecedented and confusing situation.

The Stratasys Board and management team are committed to enhancing shareholder value and continue to successfully execute on the company growth strategy, taking steps to achieve that objective.

J.P. Morgan is acting as financial advisor to Stratasys, and Meitar Law Offices and Wachtell, Lipton, Rosen & Katz are serving as legal counsel.

About Stratasys

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, healthcare, fashion and education. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the Company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

Stratasys is a registered trademark and the Stratasys signet is a trademark of Stratasys Ltd. and/or its subsidiaries or affiliates. All other trademarks are the property of their respective owners.

Cautionary Statements Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. For a discussion of some of the risks and important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements, see the discussion in Item 3.D “Key Information – Risk Factors”, Item 4 “Information on the Company”, and Item 5 “Operating and Financial Review and Prospects” in the Company’s Form 20-F for the fiscal year ended December 31, 2022.

Important Additional Information

This news release is not an offer to purchase or a solicitation of an offer to sell the ordinary shares of Stratasys. If Nano or one of its affiliates commences a tender offer for Stratasys ordinary shares, Stratasys will file with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9. STRATASYS SHAREHOLDERS ARE ADVISED TO READ STRATASYS’ SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IF AND WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY DECISION WITH RESPECT TO ANY TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stratasys shareholders may obtain a copy of the Solicitation/Recommendation Statement on Schedule 14D-9 (if and when it becomes available), as well as any other documents filed by Stratasys in connection with any tender offer by Nano or one of its affiliates, free of charge at the SEC’s website at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents from Stratasys by directing a request to Stratasys Ltd., 1 Holtzman Street, Science Park, P.O. Box 2496, Rehovot 7612, Israel, Attn: Yonah Lloyd, CCO / VP Investor Relations, or by calling +972-74-745-4029.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005204/en/

Investor Relations

Yonah Lloyd

CCO / VP Investor Relations

[email protected]

U.S. Media

Ed Trissel / Joseph Sala / Kara Brickman

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

OR

Israel Media

Motti Scherf

[email protected]

+972527202700

KEYWORDS: Minnesota United States North America Israel Middle East

INDUSTRY KEYWORDS: Consumer Electronics Aerospace Technology Manufacturing Other Technology Other Manufacturing Software Textiles Hardware Electronic Design Automation Chemicals/Plastics

MEDIA:

Posted on April 13, 2023 7:03 am

Rockwell Automation to Report Second Quarter Fiscal 2023 Results

Rockwell Automation to Report Second Quarter Fiscal 2023 Results

MILWAUKEE–(BUSINESS WIRE)–
Rockwell Automation, Inc. (NYSE: ROK) is scheduled to report its second quarter fiscal 2023 results on Thursday, April 27, before the market opens. The release will be posted on the Rockwell Investor Relations website at www.rockwellautomation.com/en-us/investors.html.

A conference call to discuss the quarterly results will be held at 7:30 a.m. CDT on April 27. This call will be audio webcast and accessible on the Rockwell website. Presentation materials will also be available on the website prior to the call.

Interested parties can access the conference call by dialing the following numbers: +1 (888) 330-2022 in the U.S. and Canada; +1 (646) 960-0690 for other countries. Use the following passcode: 5499533. Please dial in 10 minutes prior to the start of the call.

Both the presentation materials and a replay of the call will be available on the Investor Relations section of the Rockwell website through May 26.

About Rockwell Automation

Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005205/en/

Aijana Zellner

Head of Investor Relations and Market Strategy

+1 414-382-8510

[email protected]

Ed Moreland

Head of Government Affairs and External Communications

+1 571-296-0391

[email protected]

KEYWORDS: Wisconsin Illinois United States North America

INDUSTRY KEYWORDS: Technology Automotive General Automotive Machinery Other Manufacturing Robotics IOT (Internet of Things) Engineering Automotive Manufacturing Other Technology Aerospace Manufacturing Software Networks Internet Hardware Electronic Design Automation

MEDIA:

Logo

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma^™ Fully Digital Surgical Visualization Platform

New Technology Provides Cutting Edge Visualization, Ergonomic Positioning and Efficient Workflow

VAUGHAN, Ontario & HEIDELBERG, Germany–(BUSINESS WIRE)–
Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma^™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes. Developed to facilitate even the most complex surgical procedures, SeeLuma will be introduced in the United States and Western Europe this month with additional countries to follow.

“As part of our broader mission, Bausch + Lomb aims to provide ophthalmic surgeons around the world with innovative visualization and intraoperative diagnostic technologies that enhance the surgical experience to ultimately help deliver better patient outcomes,” said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb. “The launch of SeeLuma is an important milestone on this journey, as it will serve as one of the key foundations for our future image-guided surgical applications.”

SeeLuma features include a heads-up 3D monitor, multiple digital display options and an intuitive interface that contribute to excellent visualization, ergonomics, smooth workflow and an immersive educational experience.

“SeeLuma addresses several challenges that many surgeons often struggle with when using surgical microscopes that are currently available,” said Siegfried Priglinger, professor, director and chairman, University Eye Hospital of the Ludwig-Maximilians-Universität, Munich, Germany. “Having access to a platform that offers cutting edge visualization, efficient workflow and ergonomics, and educational features has the potential to really change the landscape and ultimately deliver tremendous benefits for current and future generations of surgeons, as well as their practices and patients.”

Premium Image Quality Enhances Visualization

SeeLuma offers high quality images as it relates to depth of field, color reproduction and contrast and resolution, helping surgeons tackle complicated surgical cases with confidence and ease. The platform also facilitates 3D heads-up surgery using next-generation 3D 55” and 31” 4K monitors, as well as unique digital binoculars. In addition, embedded functions allow the user to highlight and enhance anatomical landmarks to better distinguish anatomical features.

Multiple Digital Display Options Support Ergonomic Positioning

SeeLuma is the only microscope with multiple digital display options that enables surgeons to operate ergonomically. The C-shaped suspension arm enables surgeons to view the 55” or 31” 3D 4K monitor straight ahead of them. The digital binoculars are mounted onto a separate suspension arm and allow surgeons to take on an ergonomic posture and work with ease. Surgeons can maintain proper head and neck posture even while working with a tilted microscope camera head.

Intuitive Interface Facilitates Efficient Workflow

SeeLuma provides an intuitive interface with comprehensive settings. Key system functionality can be controlled either by nurses or directly by the operating surgeon using the on-screen menu via the foot switch. System parameters, such as zoom and focus speed, white balance, image inversion and foot control layouts, are automatically adapted to surgical steps. In addition, the user interface enables quick access to system functionality in an intuitive way similar to that of personal computers or mobile phones.

Interactive Platform Provides Immersive Educational Experience

SeeLuma helps ensure that all stakeholders, including those in and outside the operating room (OR), can participate in the procedure in an immersive way. Surgeons can connect multiple wireless displays simultaneously, allowing trainees and stakeholders to follow and anticipate surgical steps as they occur while in the OR and/or at a remote location. Surgeons can engage the platform’s Assist Mode to send and receive real-time support via touch screen interface and make annotations or notes on the surgical image, which helps enable collaboration and learning during live surgery events.

“For more than a decade, our Munich Surgical Imaging division, has been collaborating with physicians to develop surgeon-centered solutions that offer premium visualization and comfort to enhance their surgical experience,” said Kfir Azoulay, head of Corporate Strategy, Heidelberg Engineering, and managing director, Munich Surgical Imaging (MSI). “Utilizing MSI’s digital microscopy and image-guided applications expertise, coupled with Bausch + Lomb’s long-standing leadership and innovation in ophthalmology, the new SeeLuma platform will help address the increasing demand for innovative digital microscopy solutions by providing surgeons with outstanding imaging capabilities, ergonomics and digital tools to tackle even the most complex ophthalmic surgical cases.”

About Heidelberg Engineering and Munich Surgical Imaging

Heidelberg Engineering is global leader in the field of diagnostic imaging and healthcare IT solutions for ophthalmology. Munich Surgical Imaging (MSI) – a wholly owned subsidiary of Heidelberg Engineering – is a technological pioneer in the field of digital microscopy and image-guided applications. MSI’s first surgical platform in the field of ENT (Ear, Nose, and Throat) has received accolades from surgeons on key parameters, such as outstanding natural 3D image quality and blending of 3D image with preoperative data. MSI’s state-of-the-art OCT technology is powered by Heidelberg Engineering. For more information, visit https://www.heidelbergengineering.com/ or https://www.munichimaging.com/.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

^®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.

Any other product/brand names and/or logos are trademarks of the respective owners.

© 2023 Bausch & Lomb Incorporated or its affiliates.

SRG.0021.USA.23

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005102/en/

Heidelberg Engineering:

Kfir Azoulay

[email protected]

Bausch + Lomb Investor:

Arthur Shannon/Allison Ryan

[email protected];[email protected]

(877) 354-3705 (toll free); (908) 927-0735

Bausch + Lomb Media:

Lainie Keller/Kristy Marks

[email protected];[email protected]

(908) 927-1198; (908) 927-0683

KEYWORDS: Germany Europe North America Canada

INDUSTRY KEYWORDS: Technology Surgery Medical Devices Health Technology Audio/Video Biotechnology Health General Health Optical

MEDIA:

Logo

New Jersey Resources Schedules Fiscal 2023 Second Quarter Earnings Call

WALL, N.J.–(BUSINESS WIRE)–
New Jersey Resources (NYSE: NJR) invites investors, customers, members of the financial community and other interested parties to listen to a live webcast of its fiscal 2023 second quarter financial results on Thursday, May 4, 2023, at 10 a.m. ET.

President and Chief Executive Officer Steve Westhoven and Senior Vice President and Chief Financial Officer Roberto Bel will present an overview of NJR’s financial and operational performance for the second quarter of fiscal 2023.

A few minutes prior to the webcast, visit www.njresources.com and select “Investor Relations.” Scroll down and click the webcast link under “Latest Events” on the right side of the page.

About New Jersey Resources

New Jersey Resources (NYSE: NJR) is a Fortune 1000 company that, through its subsidiaries, provides safe and reliable natural gas and clean energy services, including transportation, distribution, asset management and home services. NJR is composed of five primary businesses:

• New Jersey Natural Gas, NJR’s principal subsidiary,operates and maintains over 7,700 miles of natural gas transportation and distribution infrastructure to serve more than 570,000 customers in New Jersey’s Monmouth, Ocean and parts of Morris, Middlesex, Sussex and Burlington counties.

• Clean Energy Ventures invests in, owns and operates solar projects with a total capacity of more than 430 megawatts, providing residential and commercial customers with low-carbon solutions.

• Energy Services manages a diversified portfolio of natural gas transportation and storage assets and provides physical natural gas services and customized energy solutions to its customers across North America.

• Storage and Transportation serves customers from local distributors and producers to electric generators and wholesale marketers through its ownership of Leaf River Energy Center and the Adelphia Gateway Pipeline, as well as our 50% equity ownership in the Steckman Ridge natural gas storage facility.

• Home Services provides service contracts as well as heating, central air conditioning, water heaters, standby generators, solar and other indoor and outdoor comfort products to residential homes throughout New Jersey.

NJR and its nearly 1,300 employees are committed to helping customers save energy and money by promoting conservation and encouraging efficiency through Conserve to Preserve® and initiatives such as The SAVEGREEN Project® and The Sunlight Advantage®.

For more information about NJR: www.njresources.com.

Follow us on Twitter @NJNaturalGas.

“Like” us on facebook.com/NewJerseyNaturalGas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005877/en/

Media Contact:

Mike Kinney

732-938-1031

[email protected]

Investor Contact:

Adam Prior

732-938-1145

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Alternative Energy Energy Utilities Oil/Gas

MEDIA:

Logo